RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing
Sionna Therapeutics Prices Upsized Initial Public Offering
The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding any exercise of the underwriters’ option to purchase additional shares of common stock.
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Glucot (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.
Volcon, Inc. Announces Pricing of $12.0 Million Underwritten Public Offering
Volcon, Inc. (NASDAQ:VLCN) (the “Company”), the first all-electric, off-road powersports company, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the
RenovoRx Announces Pricing Of Public Offering Of About 11.52 Million Shares At $1.05/shr
RenovoRx Inc. (RNXT) announced the pricing of a firm commitment, underwritten public offering of about 11.52 million shares of its
Volcon, Inc. Announces Launch of Proposed Public Offering
Volcon, Inc. (Nasdaq:VLCN) (the “Company”), the first all-electric, off-road powersports company, today announced that it has commenced a public offering to offer and sell securities, including shares of
Mustang Bio sets terms for $8M public offering
WORCESTER, Mass. - Mustang Bio , Inc. (NASDAQ:MBIO), a biopharmaceutical company engaged in the development of cell therapies for cancer treatment, has announced the pricing of a public offering expected to raise approximately $8 million.
Mustang Bio Prices Public Offering Of 2.65 Mln At $3.01/shr; Stock Down In Pre-market
Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company, Thursday announced the pricing of a public offering of 2.65
Hosted on MSN1d
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering
Nuvectis Pharma (NVCT) announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a ...
Morningstar8d
Immunome Announces Proposed Public Offering of Common Stock
In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public ...
Nasdaq9d
Akero Therapeutics Announces Pricing of Upsized Public Offering for $350 Million
Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...
RenovoRx launches public stock offering
MOUNTAIN VIEW, Calif. - RenovoRx , Inc. (NASDAQ:RNXT), a $35.7 million market cap developer of targeted oncology therapies, has initiated an underwritten public offering of its common stock and ...
Morningstar10d
Akero Therapeutics Announces Proposed Public Offering of Common Stock
In addition, Akero intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting ...